ArticleBioengineering & translational medicine2024
Cowpea mosaic virus intratumoral immunotherapy maintains stability and efficacy after long-term storage.
Article in Bioengineering & translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics.Chemical science · 2026Review
- Bioprinting collagenase-responsive hydrogel for controlled release of cowpea mosaic virus immunotherapy.Biofabrication · 2026Article
- Streamlined molecular farming of plant virus therapeutics for space flight and other low-resource environments.NPJ science of plants · 2026Article
- Irreversible electroporation with intratumoral plant virus immunotherapy induces systemic immunity in a metastatic model of pancreatic cancer.Cancer letters · 2025Article
- Toward Translation of Cowpea Mosaic Virus Intratumoral Immunotherapy With a Scalable Production Process.Plant biotechnology journal · 2025Article
- Storage stability of cowpea mosaic virus cancer drug candidate - a two-year update.Nanomedicine (London, England) · 2025Article
- Structure-function relationship of S protein cleavage in cowpea mosaic virus intratumoral immunotherapy.Biomaterials science · 2025Article
- Charting new frontiers in nanoparticle immunotoxicity: A perspective on current, emerging, and future approaches.Biochemical and biophysical research communications · 2025Review
- Intratumoral Immunotherapy with Cowpea Mosaic Virus and Interleukin-12 Eliminates Established Treated Tumors and Generates Robust Systemic Immunity to Suppress the Growth of Untreated Metastatic Tumors.Molecular pharmaceutics · 2025Article
- Preclinical SC and IV repeat-dose toxicology of a cowpea mosaic virus - A cancer immunotherapy candidate.Toxicology reports · 2025Article
- A cowpea mosaic virus adjuvant conjugated to liposomes loaded with tumor cell lysates as an ovarian cancer vaccine.Nature communications · 2025Article
- Immunomodulatory effects of intratumoral cowpea mosaic virus and calreticulin nanoparticles in canine tumors: early results.Frontiers in immunology · 2025Article
- Cowpea mosaic virus intratumoral immunotherapy maintains stability and efficacy after long-term storage.Bioengineering & translational medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cowpea mosaic virus (CPMV) has demonstrated superior immune stimulation and efficacy as an intratumoral immunotherapy, providing a strong argument for its clinical translation. One important consideration for any new drug candidate is the long-term stability of the drug and its formulation. Therefore, our lab has evaluated the physical stability and biological activity, that is, anti-tumor potency, of formulations of CPMV in buffer (with and without a sucrose preservative) in multiple temperature conditions ranging from ultralow freezers to a heated incubator over a period of 9 months. We found that non-refrigerated temperatures 37°C and room temperature quickly led to CPMV destabilization, as evidenced by significant protein and RNA degradation after just 1 week. Refrigerated storage at 4°C extended physical stability, though signs of particle breakage and RNA escape appeared after 6 and 9 months. CPMV stored in frozen conditions, including -20°C, -80°C, and liquid N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.